

DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER

ASTHMA GUIDELINE

LEGAL DISCLAIMER: The information provided by Dell Children's Medical Center (DCMC), including but not limited to Clinical Pathways and Guidelines, protocols and outcome data, (collectively the "Information") is presented for the purpose of educating patients and providers on various medical treatment and management. The information should not be relied upon as complete or accurate; nor should it be relied on to suggest a course of treatment for a particular patient. The Clinical Pathways and Guidelines are intended to assist physicians and other health care providers in clinical decision-making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment regarding care of a particular patient must be made by the physician in light of the individual circumstances presented by the patient. DCMC shall not be liable for direct, indirect, special, incidental or consequential damages related to the user's decision to use this information contained herein.

Definition:

Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Symptoms may worsen in the evening or in the morning. (GINA Global Strategy for Asthma Management and Prevention, 2023) Asthma is one of the most common chronic disorders in children and is one of the leading causes of school absenteeism.

Etiology:

Although the exact etiology of asthma is unknown, environmental factors and allergens are known factors influencing exacerbations.

Differential Diagnosis:

GERD Other causes of chronic aspiration Recurrent VLR Sinusitis Foreign body aspiration

Guideline Eligibility Criteria:

Patients 2 to 18 years of age with acute asthma exacerbation

Guideline Exclusion Criteria:

Bronchiolitis Cystic Fibrosis Tracheostomy Neuromuscular disease Immunodeficiency Cardiac disease Other Chronic Lung Disease (unless otherwise specified)

Diagnostic Evaluation:

History and physical pertinent to the exacerbation should be completed concurrently with prompt initiation of treatment. (GINA Global Strategy for Asthma Management and Prevention, 2023) **History:**

Assess for severity and duration of symptoms, medication history, risk factors and common times or exacerbations to onset of symptoms.

Physical Examination:

To include- assessment of dyspnea, respiratory rate, work of breathing, presence and location of wheezing, need for oxygen *Laboratory Tests:*

None recommended for uncomplicated asthma exacerbation

Critical Points of Evidence

Evidence Supports

Use of a common scoring tool and pathway to categorize severity and improve clinical outcomes Oxygen for saturation consistently below 90%

Short-acting beta-agonist as soon as treatment can be started Glucocorticosteroids within the first hour of arrival to hospital/ED Ipratropium bromide for moderate to severe asthma Intravenous magnesium sulfate for treatment of moderate to severe asthma

Evidence Lacking/Inconclusive

Terbutaline and epinephrine should be given only if aerosolized treatments are not tolerated or the patient has not been responsive to treatments listed above

Non-invasive positive pressure ventilation prior to intubation *Evidence Against*

Chest x-ray not recommended for routine cases Blood gas Heliox

Practice Recommendations

Treatments for asthma have been widely studied and recommendations adopted based on studied and recommended standards of care. Many of these standards of care have been adopted by the Joint Commission and were set forth as Orynx measures for pediatric healthcare agencies.

Common Asthma Scoring Tool: Modified Quereshi PAS

Measuring response to therapy can be a very useful tool in the management of asthma. No universal pediatric asthma scoring tool has been identified as superior, but there are several in the literature that have been validated and implemented in clinical practice. Our institution has adopted a modified version of the Quereshi Pediatric Asthma Score.



Treatment Recommendations

(for full recommendations see attached pathway and addendums)

Beta-agonist dosing (albuterol)

Emergency Department (PAS score Q1 hour)

1st hour

- Mild (PAS 0): No treatment required
- Mild (PAS 1-2): Albuterol 5 mg neb
- Moderate (PAS 3-5): Albuterol neb over 1 hour (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)
- Moderate to Severe (PAS 6-10): Albuterol Continuous (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)

2nd hour

- Mild (PAS 0-2): Discharge home
- Moderate (PAS 3-5): Albuterol neb over 1 hours (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)
- Moderate to Severe (PAS 6-7): Albuterol over 1 hour (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)
- Severe (PAS 8-10): Albuterol Continuous
- (<20 kg: 10 mg neb or \geq 20 kg: 15 mg neb) 3^{rd} hour
- Mild (PAS 0-2): Discharge home
- Moderate (PAS 3-5): Albuterol neb over 1 hour (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)
- Moderate to Severe (PAS 6-7): Albuterol over 1 hour (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb)
- Severe (PAS 8-10): Albuterol Continuous (<20 kg: 15 mg neb or <u>></u>20 kg: 20 mg neb)
- Inpatient (PAS score Q4hr unless otherwise noted)
 - Mild: Albuterol Q4 hours (8 puffs with inhaler)
 - Moderate: Albuterol Q3 hours (<20 kg: 5 mg neb or <u>></u>20 kg: 7.5 mg neb)
 - Moderate to Severe: Albuterol Continuous
 - (<20 kg: 10 mg neb or ≥20 kg: 15 mg neb, Q2hr PAS scores at minimum)</p>
 - Severe: Albuterol Continuous (<20 kg: 15 mg neb or ≥20 kg: 20 mg neb, Q2hr PAS scores at minimum)

Steroids

There is strong evidence that corticosteroids speed the resolution of airflow obstruction and reduce rate of relapse, especially if given within the 1st hour of admission to ED.

- **Recommended: Dexamethasone** has shown to be just as effective as prednisolone and has the added benefit of decreased vomiting and less doses, thus increasing compliance.
 - Dosing: Dexamethasone 0.6 mg/kg PO/IM/IV (max: 16 mg) once daily x2 doses (Separate the 2 doses by 24-36 hours)
 - For dexamethasone allergy or intolerance: Prednisolone
 - Dosing: Prednisolone 1 mg/kg/day PO Q12hr (max: 20 mg/dose Q12 or 40 mg/dose Qday) for 5 days total steroid exposure

- Severe exacerbations Methylprednisolone
 - o Initial Dose: Methylprednisolone 1 mg/kg IV x1 (max: 30 mg)
 - (skip this step if methylprednisolone or dexamethasone already given)
 - 6 hours later: methylprednisolone 0.5 mg/kg IV Q6h (max: 30mg/dose)
- Full recommendations and methylprednisolone weaning instructions are supplied in addendum 1

Ipratropium Bromide

Strongly recommended as an adjunctive therapy for patients with moderate to severe symptoms (1st hour)

 Dosing: Ipratropium 1 mg via neb- in conjunction with Albuterol in the 1st hour

Magnesium Sulfate

Strong recommendation to be used as an adjunctive therapy when there is no response to conventional therapies.

- Dosing: Magnesium Sulfate 50 mg/kg IV (max 2 g) over 20-30 min. x1
 - Strongly consider NS bolus if not already given
 Only one dose may be administered on acute care units, other than pediatric intensive care, in a 24 hour period

Terbutaline

Terbutaline and epinephrine should be given only if aerosolized treatments are not tolerated or the patient has not responded to treatments listed above

- Dosing: 10 mcg/kg SQ (Max 250 mcg=0.25 mL) X1 for child in extremis (can be given q20min x 3 doses until IV established)
 - o If considering IV Terbutaline it must be ordered in concert with STAT PICU consult
 - Recommended starting dose: 10 mcg/kg (max 250 mcg) IV load over 15 minutes
 - followed by continuous IV drip 0.4 mcg/kg/min
 - o STAT call to Pharmacy for IV drip Terbutaline

Pediatric Intensive Care ONLY Ketamine

 Dosing Ketamine 5 mcg/kg/minute continuous IV infusion (*titrate per protocol to meet sedation needs*)



Admission Criteria Supplemental oxygen requirement

No improvement to baseline after multiple respiratory treatments Stage 1 (Score 1-2) = Acute Care Unit

*Note: Discharge is recommended for scores of 0-2, admission will only occur for score 0-2 if oxygen is required or there is concern for deterioration

Stage 2 (Score 3-5) = Acute Care Unit

Stage 4 (Score 6-7) = Acute Care Unit

Stage 5 (Score 8-10) = Pediatric Intensive Care Unit

Consults and Referrals

Pulmonology for patients with chronic symptoms and multiple admissions

Infection Control

Standard isolation only unless viral factors are suspected

Caregiver Education

Children should not be exposed to passive smoke, explore smoking cessation opportunities as indicated Emphasize importance of follow-up appointments Emphasize importance of following recommendations on the Home Management Plan of Care (HMPOC)

Discharge Criteria

Albuterol - 8 puffs or 5 mg q4hr or longer and receive at least 1 dose Oxygen Saturation >90 for more than 2 hours

Follow-Up Care

Generally, follow-up care is 1 - 2 days post-discharge with the primary care doctor


Prevention

Caregiver and patient knowledge of HMPOC Knowledge of common triggers and how to prepare or avoid Proper use and understanding of inhaled corticosteroids and controller medications Asthma Action Plan

Outcome Measures

Emergency Department (ED): Time from ED triage to administration of beta-agonist Time from ED triage to administration of steroids Proportion receiving 1st neb within 60 minutes of arrival Proportion receiving steroid within 60 minutes of arrival Proportion of patients assessed for understanding of HMPOC Readmissions to ED within 30 days and within 12 months

Inpatient (IP): Proportion of patients with a documented HMPOC Proportion of patients assessed for their understanding of HMPOC Average length of stay




Last updated: June 2024

Inpatient Asthma Pathway Guidelines

• Reassess PAS score with every treatment • Supplemental O2 to maintain SaO2 >90% • Smoking cessation counseling when indicated





dell children's Last updated: June 2024

Ascension

Pediatric Intensive Care Asthma Pathway Guidelines

Inclusion criteria:

- Patients 2-18 years of age with acute asthma exacerbation
- Poor responders to treatment
- Patients in Extremis
- Patients Scoring 8 or higher on the PAS
- Patients not showing improvement within 6 hours of admission to the Acute Care Unit

Standards of Care (care every patient will receive)

<u>Albuterol Continuous Nebulizer:</u>

PAS 8-10= < 20 kg = 15 mg/hr or \ge 20 kg = 20 mg/hr

PAS 6-7= < 20 kg = 10 mg/hr or \geq 20 kg = 15 mg/hr once patient is weaned from terbutaline & magnesium sulfate drip Respiratory Therapy will score the patient, at a minimum, every two hours

Respiratory Therapy will contact the Physician/ Mid-level / Resident for weaning orders

Please see Inpatient Asthma Pathway Guidelines for dosing once patient is deemed ready to be off continuous nebs

 <u>Methylprednisolone</u>: 0.5 mg/kg IV Q6 hours x 24 hours (max: 30 mg per dose) (see Addendum 1 for methylprednisolone management and weaning guidelines)

 \Box <u>Ipratropium</u>: < 20 kg - 0.25 mg or > 20 kg - 0.5 mg inhaled Q6 hours x 24 hours

□ Magnesium Sulfate: 50 mg/kg IV (2 grams max) Over 20-30 minutes (if not given in ED or Acute Care Unit)

Medications for Refractory Treatment

- □ <u>Ipratropium</u>: < 20 kg 0.25 mg or ≥ 20 kg 0.5 mg inhaled Q6 hours, may continue per physician discretion if necessary</p>
- <u>Terbutaline</u>: Loading dose 10 mcg/kg (max: 250 mcg) over 15 minutes followed by continuous IV infusion 0.4 mcg/kg/minute

Terbutaline infusion should be weaned to off before weaning continuous Albuterol

- □ <u>Magnesium Sulfate</u>: < 30 kg 25 mg/kg/hr or ≥ 30 kg 20 mg/kg/hr continuous IV infusion (max: 2 g per hour) Check serum magnesium 2 hours after the infusion is started then Q8 hours (serum magnesium target = 3-5 mg/dL) *Titrate by 5 mg/kg/hr based on serum levels*
- □ <u>Ketamine</u>: 5 mcg/kg/minute continuous IV infusion

Titrate per protocol to meet sedation needs

Recommendations for Discharge or Transfer out of the Pediatric Intensive Care Unit

• DISCHARGE HOME

PAS 1-2 (ready for discharge home) - See Addendum 4 for Discharge Readiness Criteria and Requirements

- ADMIT TO ACUTE CARE UNIT PAS 1-2 (NOT ready for discharge home) PAS 3-5
- ADMIT TO IMC

PAS 6-7 (not exhibiting steady improvement, but no longer requiring PICU care)





Ascension Texas

Austin, TX 78723

Pediatric Asthma Albuterol Titration Protocol Severity Score Sheet

Year: Date (month, day):									
Initials: Credentials (example: RN, RT):									
	Pre or Post Score? <u>RT ONLY</u> :								
	Circle the appropriate asse	ssmen	t score	e below	/.				
	Enter Respiratory Rate (If obtained over 30 seconds, multiply by 2)	Rate	Rate		Rate	Rate	Rate	Rate	Rate
	2-3 yrs: 34 or Less Breaths per Minute 4-5 yrs: 30 or Less Breaths per Minute 6-12 yrs: 26 or Less Breaths per Minute >12 yrs: 23 or Less Breaths per Minute	0	0	0	0	0	0	0	0
Respiratory	2-3 yrs: 35-39 Breaths per Minute 4-5 yrs: 31-35 Breaths per Minute 6-12 yrs: 27-30 Breaths per Minute >12 yrs: 24-27 Breaths per Minute	1	1	1	1	1	1	1	1
	2-3 yrs: 40 or More Breaths per Minute 4-5 yrs: 36 or More Breaths per Minute 6-12 yrs: 31 or More Breaths per Minute >12 yrs: 28 or More Breaths per Minute	2	2	2	2	2	2	2	2
Room Air Room Air O2 Sat. More Than 95%		0	0	0	0	0	0	0	0
Oxygen	Room Air O2 Sat. 90-95% RA SpO2	1	1	1	1	1	1	1	1
Saturation	Room Air O2 Sat. Less than 90%	2	2	2	2	2	2	2	2
	Clear BS or End Expiratory Wheezes	0	0	0	0	0	0	0	0
Auscultation	Expiratory Wheezes	1	1	1	1	1	1	1	1
Auscultation	Inspiratory & Expiratory Wheezes or Diminished Breath Sounds		2	2	2	2	2	2	2
Morth of	Use of 0-1 Accessory Muscles	0	0	0	0	0	0	0	0
Work of Breathing	Use of 2 Accessory Muscles	1	1	1	1	1	1	1	1
Drouting	Use of 3 or More Accessory Muscles	2	2	2	2	2	2	2	2
	Full Sentences, Playful, Babbles	0	0	0	0	0	0	0	0
Dyspnea	Partial Sentences, Short Cry	1	1	1	1	1	1	1	1
(Speaks in)	Short Phrases, Single Words, Grunting	2	2	2	2	2	2	2	2
Total Asthma Severity Score (0-10)									
Asthma Protocol Stage <u>RT ONLY</u>									
Albuterol Dose Given (mg) RT ONLY									
Next Assessment Time									
Signature, Initials:			Signature, Initials:						
Signature, Initials:			Signature, Initials:						





Patients started on methylprednisolone (Solumedrol) should complete their steroid course with prednisolone (Orapred).


Exception:

If patient has received only one dose of methylprednisolone then they can receive the 2 doses of dexamethasone (Decadron) as is outlined in the ED and Inpatient Pathways.





ADDENDUM 2: Ordering Instructions for Inhalers at Discharge





Addendum 3 Inhaled Corticosteroids for Asthma

Generic Name	Brand	Low Daily Dose (mcg)			Medium Daily Dose (mcg)			High Daily Dose (mcg)		
Generic Maine	Name	0-4 yr	5-11 yr	≥ 12 yr	0-4 yr	5-11 yr ≥ 12 yr		0-4 yr 5-11 yr		\geq 12 yr
Beclomethasone HFA 40 or 80 mcg/puff	Qvar, Qvar RediHaler	N/A	40-80	80-240	N/A	160	240-480	N/A	320	> 480
Budesonide DPI 90,180,200 mcg/inh	Pulmicort Flexhaler	N/A	100-200	200-400	N/A	200-400	400-800	N/A	>400	>800
Budesonide neb 0.25mg/2ml, 0.5mg/2ml	Pulmicort	0.5mg	0.25-0.5mg	N/A	0.5-1mg	0.5-1mg	N/A	> 1mg	2mg	N/A
Budesonide/Formoterol HFA: 80/4.5, 160/4.6	Symbicort	N/A	160	160	N/A	320	320	N/A	320	640
Ciclesonide HFA 80, 160 mcg/puff	Alvesco	N/A	80	80-160	N/A	160	160-320	N/A	320	320-640
Fluticasone HFA 44,110,220 mcg/puff	Flovent	176 (mask)	88-176	88-220	176-440 (mask)	220-440	440	> 440 (mask)	880	880
Fluticasone/Salmeterol HFA: 45/21,115/21,230/21	Advair	180 (mask)	90-180	90-230	460 (mask)	230-460	460	920 (mask)	920	920
Fluticasone/Salmeterol Disk: 100/50,250/50,500/50	Advair	N/A	200	200	N/A	500	500	N/A	1000	1000
Mometasone DPI 110,220 mcg/inh	Asmanex	N/A	110	110-200	N/A	220-440	220-440	N/A	> 440	>440
Mometasone/Formoterol HFA: 50/5, 100/5, 200/5	Dulera	N/A	100	200	N/A	100	400	N/A	200	800

N/A = Dosing not available in this age group, MDI = metered dose inhaler, HFA = hydrofluoroalkane inhaler, DPI = dry powder inhaler

Addendum 4 Asthma Discharge Checklist



Clinical Readiness for Discharge

- □ Albuterol 8 puffs or 5 mg Q4 times 1 dose
- □ Oxygen Saturation >90 for more than 2 hours

Items Required for Discharge Home

- Asthma Action Plan
- Asthma Education

 Influenza Vaccine per hospital protocol if not already received for the year (not applicable in ED- refer to primary provider)

- Order Albuterol MDI and re-label for home use with applicable home instructions
 - <u>Relabel</u> Albuterol inhaler with instructions for use <u>after</u> discharge. If albuterol to be rescheduled after discharge, be specific about dosing schedule and when to change to PRN (if applicable).
 - Note: If less than 100 puffs left in the albuterol inhaler, in addition to relabeling, enter a prescription for albuterol MDI.
- Prescription for Controller (addendum 2)
- Steroids: Dexamethasone script for dose #2- 0.6 mg/kg PO x1 (max: 16mg rounded to nearest 1 or 4mg tab) if second dose was not received in the hospital

Family education/ prescription instructions:

Give 24-36 hours after the initial dose, with the 2nd dose preferably in the morning. Crush and mix in a small bite of food or a teaspoon of liquid that the child prefers.

If the patient received methylprednisolone (Solumedrol) or prednisolone (Orapred), see addendum 1 for steroid management and write an applicable prescription to finish the course of treatment.

Smoking Cessation, if indicated







The exclusion criterion to be applied to potential Acute Care Unit (asthma high-acuity) admissions does not supersede clinician decision-making. Should the clinician feel that the child's placement would be better-suited in a higher level of care despite the presence of exclusion criteria; the clinician's decision should be honored. **None of the below criteria should delay disposition per agreed time criteria between ED/PCRS/ICU.**

- Level of Consciousness
 - o If there is any question of altered mental status being present, the child is no longer appropriate for high-acuity unit placement.
- Blood Pressure
 - Common blood pressure side-effects from bronchodilators are increased systolic and decreased diastolic pressures. NS bolus should be considered once BP fall below normal range.
 - Should the child's diastolic blood pressure fall below normal standards (not critical low value) without improvement after ONE NS bolus, the child is excluded.
 - Should the child report chest pain in the context of low diastolic blood pressure, then the child is excluded regardless of NS bolus administration.

VITAL SIGNS REFERENCE CARDS 2011						
	AGE GROUPS FROM COMPASS	NORMAL RANGE	CRITICAL LOW			
s	0 – 8 days	65-95	60	100		
SYSTOLIC	9 – 28 days	65-95	60	100		
	29d – 12m	75-95	70	100		
BLOOD	13m – 3yr	80-95	75	110		
	4 — буг	85-110	80	120		
PRESSURE	7–13yr	95-130	90	140		
SUR	14 – 18yr	95-140	90	150		
•	>18yrs	92-170	90	180		
Þ	0 — 8days	35-71	30			
IST	9 – 28days	35-69	30			
DIASTOLIC	29d – 12mo	35-73	30			
BLOOD	13mo – 3yr	35-73	30	~~~		
19	4 — буг	45-73	40			
PRES	7–13yr	45-81	40			
PRESSURE	14 – 18yr	45-84	40			
Ē	>18yrs	70-100	50	110		

- Pulmonary Insufficiency
 - o Oxygen use alone is not a reason to exclude from admission.
 - After beta-agonist Rx has been applied and 15-20 minutes have passed to allow for equilibration of V/Q mismatch, if the child has **new onset need for** oxygen of greater than 50% FiO₂ then the patient is excluded.

Any patient in an acute care unit scoring an 8 or more should be under the care of the PICU team.

Addendum 6: Dexamethasone (Oral) for the Treatment of Asthma

Administration Information

Children with asthma exacerbation and a Pediatric Asthma Score (PAS) of 3 or more will be given steroids within 1 hour of arriving in the emergency department. When possible, oral dexamethasone (Decadron) will be given at a dose of 0.6 mg/kg (Max 16 mg) x 1 dose.

If the patient cannot swallow tablets, the dexamethasone tabs can be crushed up and mixed with 3-5 ml of Syrpalta (grape syrup) or a bite of applesauce/pudding/ice cream.

For ease of dosing, consider rounding the dexamethasone to the nearest 4mg tab using these weight ranges:

- 8 to 10.9 kg = 6 mg
- 11 to 15.9 kg = 8 mg
- 16 to 23.9 kg = 12 mg
- 24 kg and above = 16 mg

Based on these ranges, the 4 mg tab(s) can be used for all patients and crushed for those too young to swallow it.

One dose of dexamethasone (dosed as mentioned above) will provide anti-inflammatory treatment for 1-2 days. Most patients will not need another dose for at least 24 hours and patients with mild asthma exacerbation may not need another dose. Those with moderate exacerbation will need 2 doses separated by 24-36 hours. More than 2 doses of dexamethasone has not been studied for the treatment of asthma exacerbation.

Outpatient prescriptions for dexamethasone should be written using the 4 mg tabs and rounding to the nearest whole tab (using the weight ranges and doses above) x 1 dose po to be given 24 hrs following the ED or hospital time of administration. Pediatricians should write for a total of 2 doses to be given, separated by 24-36 hours with the first dose given as soon as possible. Additionally, there should be a sentence that states "crush tab(s) between two metal spoons and mix with 1 tsp of juice or 1 bite of food". All outpatient pharmacies carry the 4 mg tabs.

Best Practice Points to Remember

- To meet the 1 hour metric for corticosteroids, it is best to have the 4 mg tabs loaded in your Omnicell.
- Tabs are the best dosage form for dexamethasone because the commercially available dexamethasone elixir is 30% alcohol and associated with a high rate of emesis.
- Parents should be counseled to give the second dose with food, in the morning, 24-36 hrs after the first dose (due to the common side effect of insomnia/hyperactivity).





DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER



Approved by the Pediatric Asthma Evidence-Based Outcomes Center Team

Revision History

Date Approved: June 11, 2014 Revision Date: March 2019, November 2022, June 2024 June 2024 - Full Review. Pharm Steroid Med updates, Change reference to "floor" and "Pulm Unit" to Acute Care Unit, Update Addendum 1 (inpatient wean algorithm updated), Addendum 2 (added Dulera), Addendum 3 (removed Triamcinolone, updated Mometasone/Formoterol dosing), replaced old with new Ascension Texas Pediatric Asthma Albuterol Titration Protocol Severity Score Sheet.

Next Full Review: June 2028

EBOC Leadership Committee:	Asthma Workgroup:
Sarmistha Hauger, MD	Jenna Summerlin, PharmD
Patty Click, RN	Kelly Bundick, PharmD
Sheryl Yanger, MD	Jessica Overgoner, MSRC, RRT-NPS
Tory Meyer, MD	Keith Kerr, MD
Nilda Garcia, MD	Paul Bauer, MD
Meena lyer, MD	Tara Kirkendall, RRT-NPS
Lynn Thoreson, DO	Amanda Puro, MD
Amanda Puro, MD	Joseph Tayar, MD
Lynsey Vaughan, MD	Michael Auth, MD
	Neesha Jayasuriya, RRT-NPS
	Sheryl Yanger, MD
	Mary Karr, PharmD
	Jessica Grunwald, PharmD
	Hai Quyen Tran, Pharm D

Recommendations

Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible.

Approval Process

EBOC guidelines are reviewed by DCMC content experts, the EBOC committee, and are subject to a hospital-wide review prior to implementation. Recommendations are reviewed and adjusted based on local expertise.

LEGAL DISCLAIMER: The information provided by Dell Children's Medical Center (DCMC), including but not limited to Clinical Pathways and Guidelines, protocols and outcome data, (collectively the "Information") is presented for the purpose of educating patients and providers on various medical treatment and management. The information should not be relied upon as complete or accurate; nor should it be relied on to suggest a course of treatment for a particular patient. The Clinical Pathways and Guidelines are intended to assist physicians and other health care providers in clinical decision-making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines should not be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment regarding care of a particular patient must be made by the physician in light of the individual circumstances presented by the patient. DCMC shall not be liable for direct, indirect, special, incidental or consequential damages related to the user's decision to use this information contained herein.

References



Beta-Agonist

- SIGN: British Guideline on the Management of Asthma: Scottish Intercollegiate Guidelines Network. (2012). *Thorax*. 63 Suppl⁴: iv1⁻121. <u>http://www.sign.ac.uk/pdf/grg101.pdf</u>
- Global Initiative for Asthma (GINA). (2012). Global strategy for asthma management and prevention. Vancouver (WA): Global Initiative for Asthma (GINA). <u>http://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf</u>
- NAEPP: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report. (2007). [erratum appears in J Allergy Clin Immunol. 2008 Jun;121(6):1330]. Journal of Allergy & Clinical Immunology, 120(5 Suppl): S94-138. http://www.nhlbi.nih.gov/guidelines/asthma/
- Scarfone RJ, Friedlaender EY. (2002). Beta 2-agonists in acute asthma: the evolving state of the art. Pediatric Emergency Care, 8(6):442-427. http://pediatrics.appublications.org/content/92/4/513.abstract
- Schuh S, Reider MJ, Canny G, et al. (1990). Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics, 86(4):509-13 <u>http://www.ncbi.nlm.nih.gov/pubmed/2216613</u>

Heliox

- SIGN: British Guideline on the Management of Asthma: Scottish Intercollegiate Guidelines Network. (2012). Thorax. 63 Suppl⁴: iv1⁻121. <u>http://www.sign.ac.uk/pdf/qrg101.pdf</u>
- Bigham, M. T.; Jacobs, B. R.; Monaco, M. A.; Brilli, R. J.; Wells, D., et al. (2010). Helium/oxygen driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. *Pediatric Critical Care*, *11*(3), 356-361 http://www.ncbi.nlm.nih.gov/pubmed/20464778
- Rivera, M. L.; Kim, T. Y.; Stewart, G. M.; Minasyan, L.; and Brown, L. (2006). Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. American Journal of Emergency Medicine, 24(1): 38-42 http://www.ncbi.nlm.nih.gov/pubmed/16338507
- Rodrigo, G.; Pollack, C.; Rodrigo, C.; and Rowe, B. H. (2006). Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews, Issue 4. Art. No: CD002884 <u>http://www.ncbi.nlm.nih.gov/pubmed/14583955</u>

Ipratropium

- Dotson, K. M. D.; Dallman, M. M. D.; Bowman, C. M. M. D.; and Titus, M. O. M. D. (2009). Ipratropium Bromide for Acute Asthma Exacerbations in the Emergency Setting: A Literature Review of the Evidence. *Pediatric Emergency Care*, 25(10): 687-692
- http://www.ncbi.nlm.nih.gov/pubmed/?term=lpratropium+Bromide+for+Acute+Asthma+Exacerbations+in+the+Emergency+Setti
 Hayday, K. and Stevermer, J. J. (2002). In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome? *Journal of Family Practice*, 51(3): 280 Abstract not available
- Iramain, R.; Lopez-Herce, J.; Coronel, J.; Spitters, C.; Guggiari, J.; and Bogado, N. (2011). Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. *Journal of Asthma, 48*(3), 298-303 http://www.ncbi.nlm.nih.gov/pubmed/21332430
- Pollack C., Pollack E, Baren. M, et al. (2002). A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Archives of Pediatric Adolescent Medicine. 156(9):934-940.
- http://www.ncbi.nlm.nih.gov/pubmed/12197803
- Qureshi, F., Pestian, J., Davis, P., Zaritsky, A. (1998). Effect of nebulized ipratropium on the hospitalization rates of children with asthma. *New England Journal of Medicine* 339(15): 1030-1035
- http://www.ncbi.nlm.nih.gov/pubmed/?term=Effect+of+nebulized+ipratropium+on+the+hospitalization+rates+of+children+with+asth
 Ralston, M.E.; Euwema, M.S.; Knecht, K.R.; et al. (2005). Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. Journal of Emergency Medicine, 29(1):29-35 http://www.ncbi.nlm.nih.gov/pubmed/?term=ralston+2005+asthma
- Rodrigo, G. J. and Castro-Rodriguez, J. A. (2005). Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. *Thorax*, 60(9): 740-6 http://www.ncbi.nlm.nih.gov/pubmed/16055613
 Zorc, J.J., Pusic, M.V., Ogborn, C.J., Lebet, R., and Duggan, A.K. (1999). Ipratropium bromide added to asthma treatment in the pediatric emergency department. *Journal of Pediatrics* 103(4 Pt 1):748-52 http://www.ncbi.nlm.nih.gov/pubmed/10103297

Magnesium Sulfate

- Alter, H.J.; Koepsell, T.D.; Hilty, W.M. (2000). Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Annals Emergency Medicine 36(3):191-7 <u>http://www.ncbi.nlm.nih.gov/pubmed/10969219</u>
- Ciarallo, L.; Brousseau, D.; and Reinert, S. (2000). Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Archives of Pediatrics & Adolescent Medicine, 154(10): 979-8 http://www.ncbi.nlm.nih.gov/pubmed/?term=Higherdose+intravenous+magnesium+therapy+for+children+with+moderate+to+severe+acute+asthma
- Ciarallo, L.; Sauer, A.H.; Shannon, M.W. (1996). Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. *Journal of Pediatrics* 129(6):809-14 www.ncbi.nlm.nih.gov/pubmed/8969721
- Cheuk, D. K., Chau, T. C., & Lee, S. L. (2005). A meta-analysis on intravenuous magnesium sulphate for treating acute asthma. Achives of Disease in Childhood, 90(1), 74-77 http://www.ncbi.nlm.nih.gov/pubmed/15613519
- Devi, P.R.; Kumar, L.; Singhi, S.C.; Prasad, R.; Singh, M. (1997). Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. *Indian Pediatrics* 34(5):389-97 http://www.ncbi.nlm.nih.gov/pubmed/9332112
- Gürkan, F.; Haspolat, K.; Boşnak, M.; Dikici, B.; Derman, O.; Ece, A. (1999). Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. *European Journal of Emergency Medicine* 6(3):201-5 http://www.ncbi.nlm.nih.gov/pubmed/10622383
- Mohammed, S. and Goodacre, S. (2007). Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emergency Medicine Journal, 24(12): 823-30 http://www.ncbi.nlm.nih.gov/pubmed/18029512
- Rowe, B.H.; Bretzlaff, J.A.; Bourdon, C.; Bota, G.W.; Camargo, C.A. Jr. (2000). Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. *Annals of Emergency Medicine* 36(3):181–90 <u>http://www.ncbi.nlm.nih.gov/pubmed/10969218</u>



Magnesium Sulfate, continued

- Rowe, B. H.; Bretzlaff, J.; Bourdon, C.; Bota, G.; Blitz, S.; and Camargo, C. A. (2009). Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. *Cochrane Database of Systematic Reviews*, (3), 2009. <u>http://www.ncbi.nlm.nih.gov/pubmed/10796650</u>
- Scarfone, R.J.; Loiselle, J.M.; Joffe M.D.; Mull, C.C., Stiller, S.; Thompson, K.; et al. (2000). A randomized trial of magnesium in the emergency department treatment of children with asthma. *Annals of Emergency Medicine* 36(6):572–8 http://www.ncbi.nlm.nih.gov/pubmed/11097697
- Silverman, R.A., Osborn, H., Runge, J., Gallagher, E.J., Chiang, W., Feldman, J., et al. (2000). Acute Asthma/Magnesium Study Group. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. *Chest* 122(2):489–97 http://www.ncbi.nlm.nih.gov/pubmed/12171821
- Torres, S., Sticco, N., Bosch, J. J., Iolster, T., Siaba, A., et al. (2012). Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in childen, conducted in a tertiary-level university hospital. A randomized, controlled trial. Archives of Argentinian Pediatrics, 110(4), 291-296 http://www.ncbi.nlm.nih.gov/pubmed/22859321

Noninvasive Positive Pressure Ventilation

- Abramo, T.J. and Wiebe, R.A. (2007). Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. *Pediatric Emergency Care*, 23(6):355-361 http://www.ncbi.nlm.nih.gov/pubmed/17572517
- Bogie, A.L.; Towne, D.; Luckett, P.M.; Abramo, T.J.; Wiebe, R.A. (2007). Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. *Pediatric Emergency Care*, 23(6):355-361
 http://www.ncbi.nlm.nih.gov/pubmed/17572517
- Lafond, C.; Series, F.; and Lemiere, C. (2007). Impact of CPAP on asthmatic patients with obstructive sleep apnea. European Respiratory Journal, 29(2):307-311 http://www.ncbi.nlm.nih.gov/pubmed/17050561
- Loh, L.E.; Chan, Y.H.; and Chan, I. (2007). Noninvasive ventilation in children: a review. *Journal of Pediatrics*, 83(2 Suppl): S91 -S99 http://www.ncbi.nlm.nih.gov/pubmed/17486195
- Ram, F.S.F., Wellington, S.R., Rowe, B., and Wedzicha, J.A. (2005). Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. *Cochrane Database of Systematic Reviews*, Issues 3. Art. No.: CD004360. DOI: 10.1002/14651858.CD004360.pub3. <u>http://www.ncbi.nlm.nih.gov/pubmed/16034928</u>
- Soma, T., Hino, M., Kida, K., Kudoh, S. (2008). A prospective and randomized study for improvement of acute asthma by non-invasive positive pressure ventilation (NPPV). Internal Medicine, 47():493-501 http://www.ncbi.nlm.nih.gov/pubmed/18344635
- Yim, S., Fredberg, J.J., and Malhotra, A.(2007). Continuous positive airway pressure for asthma: not a big stretch? European Respiratory Journal, 29(2):226-228 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496923/

Oxygen

- Ribeiro de Andrade, C.; Duarte, M. C.; and Camargos, P. (2007). Correlations between pulse oximetry and peak expiratory flow in acute asthma. Brazilian Journal of Medical & Biological Research, 40(4): 485-90 <u>http://www.ncbi.nlm.nih.gov/pubmed/?term=riberro+de+andrade+2007+asthma</u>
- Geelhoed, G. L. L., ; Le Souef. (1994). Evaluation of SaÓ2 as a predictor of outcome in 280 children presenting with acute asthma. Annals of Emergency Medicine 23(6):1236-41. <u>http://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+SaO2+as+a+predictor+of+outcome+in+280+children+presenting+with+acute+asthma</u>
- Gorelick, M. H.; Stevens, M. W.; Schultz, T.; and Scribano, P. V. (2004). Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. *Pediatric Emergency Care*, 20(1): 22-6 <u>http://www.ncbi.nlm.nih.gov/pubmed/?term=Difficulty+in+obtaining+peak+expiratory+flo</u> w+measurements+in+children+with+acute+asthma
- Keahey, L.; Bulloch, B.; Becker, A. B.; Pollack Jr., C. V.; Clark, S.; Camargo Jr., C. A. (2002). Multicenter Asthma Research Collaboration, I.: Initial oxygen saturation as a predictor of admission in children presenting to the emergency department with acute asthma. *Annals of Emergency Medicine*, 40(3): 300-7 http://www.ncbi.nlm.nih.gov/pubmed/12192354
- Sole, D.; Komatsu, M. K.; Carvalho, K. V.; and Naspitz, C. K. (1999). Pulse oximetry in the evaluation of the severity of acute asthma and/or wheezing in children. *Journal of Asthma*, 36(4): 327-33 http://www.ncbi.nlm.nih.gov/pubmed/10386496

Scoring Tool: Modified Quereshi PAS

- NAEPP: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma- Summary Report. (2007). [erratum appears in J Allergy Clin Immunol. 2008 Jun;121(6):1330]. Journal of Allergy & Clinical Immunology, 120(5 Suppl): S94-138. http://www.nhlbi.nih.gov/guidelines/asthma/
- SIGN: British Guideline on the Management of Asthma: Scottish Intercollegiate Guidelines Network. (2012). Thorax. 63 Suppl4: iv1-121. <u>http://www.sign.ac.uk/pdf/grg101.pdf</u>
- Kelly, C.S.; Littelman, C.A.; Pestian, J.P., et al. (2000). Improved outcomes for hospitalized asthmatic children using a clinical pathway. Annals of Allergy, Asthma, & Immunology, 84:509-516. <u>http://www.ncbi.nlm.nih.gov/pubmed/10831004</u>
- Smith, S.R.; Baty, J.D.; and Hodge, D. (2002). Validation of the pulmonary score: an asthma severity scores for children. Academic Emergency Medicine, 9:99-104. <u>http://www.ncbi.nlm.nih.gov/pubmed/11825832</u>
- Ducharme, F.M.; Chalut, D.; Plotnick, L.; Savdie, C., et al. (2008). The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. Journal of Pediatrics, 152; 476-80. <u>http://www.ncbi.nlm.nih.gov/pubmed/18346499</u>
- Liu, L.L.; Gallaher M.M.; David, R.L.; Rutter, C.M.; et al. (2004). Use of a respiratory clinical score among different providers. Pediatric Pulmonology, 37:243-248. http://www.ncbi.nlm.nih.gov/pubmed/14966818
- Gorelick, M. H.; Stevens, M. W.; Schultz, T.; and Scribano, P. V. (2004). Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatric Emergency Care, 20(1): 22-6

http://www.ncbi.nlm.nih.gov/pubmed/?term=Difficulty+in+obtaining+peak+expiratory+flow+measurements+in+children+with+acute+asthma

General

- Lieberman JA. Trials and tribulations of managing pediatric and adolescent asthma. Ann Allergy Asthma Immunol. 2024 Jan;132(1):1-2. doi: 10.1016/j.anai.2023.10.002. PMID: 38123277.
- Goodman K, Arriaga RI, Korman R, Zafar F, Stephens C, Kumari P, Jayaprakash K, Fitzpatrick AM, Cooper N, Morris CR. Pediatric emergency department-based asthma education tools and parent/child asthma knowledge. Allergy Asthma Clin Immunol. 2024 Mar 25;20(1):24. doi: 10.1186/s13223-024-00884-w. PMID: 38528606; PMCID: PMC10964685.
- Hon KLE, Ng DKK, Chiu WK, Leung AKC. Insights from Overviewing Selective International Guidelines for Pediatric Asthma. Curr Pediatr Rev. 2024 Jan 29. doi: 10.2174/0115733963270829231221062201. Epub ahead of print. PMID: 38288811.



Steroids

- Altamimi, S., Robertson, G., Jastaniah, W., et al. (2006). Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatric Emergency Care, 22(12):786-93 <u>http://www.ncbi.nlm.nih.gov/pubmed/17198210</u>
- Andrews, A.L., Wong, K.A., Heine, et al. (2012). A cost-effectiveness analysis of dexamethasone versus prednisone in pediatric acute asthma exacerbation. Society for Academic Emergency Medicine.19, 943-948. <u>http://www.ncbi.nlm.nih.gov/pubmed/22849379</u>
 SICN: British Cuideling on the Management of Acthma: Society for Academic Emergency Medicine.19, 943-948. <u>http://www.ncbi.nlm.nih.gov/pubmed/22849379</u>
- SIGN: British Guideline on the Management of Asthma: Scottish Intercollegiate Guidelines Network. (2012). *Thorax.* 63 Suppl⁴: iv1⁻121. <u>http://www.sign.ac.uk/pdf/grg101.pdf</u>
 Camargo, C. A., Jr.; Rachelefsky, G.; and Schatz, M. (2009). Managing asthma exacerbations in the emergency department: summary of
- Camargo, C. A., Jr.; Rachelefsky, G.; and Schatz, M. (2009). Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. *Journal of Emergency Medicine*, 37(2 Suppl): S6-S17. Abstract not available
- Edmonds, M.; Camargo, C. A.; Pollack, C. V.; and Rowe, B. H. (2009). Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. *Cochrane Database of Systematic Reviews*, (4) Abstract not available
- Global Initiative for Asthma (GINA). (2012). Global strategy for asthma management and prevention. Vancouver (WA): Global Initiative for Asthma (GINA). <u>http://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf</u>
- Gordon, S., Tompkins, T., and Dayan, P.S. (2007). Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma. Pediatric Emergency Care,23(8):521-7 http://www.ncbi.nlm.nih.gov/pubmed/17726409
- Greenberg, R.A., Kerby, G., and Roosevelt, G.E. (2008). A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department. Clinical Pediatrics, (8):817-23 <u>http://www.ncbi.nlm.nih.gov/pubmed/18467673</u>
- Hames, H., Seabroock, J.A., Matsui, D. et al. (2008). A palatability study of a flavored dexamethasone preparation versus prednisolone liquid in children with asthma exacerbation in a pediatric emergency department. Canadian Journal of Clinical Pharmacology, 15 (1), 95-98. <u>http://www.ncbi.nlm.nih.gov/pubmed/18245869</u>
- Kravitz, J., Dominici, P., Ufberg, J., et al. (2011). Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial. Annals of Emergency Medicine, 58(2):200-4, 2011 http://www.ncbi.nlm.nih.gov/pubmed/21334098
- NAEPP: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report. (2007). [erratum appears in J Allergy Clin Immunol. 2008 Jun;121(6):1330]. Journal of Allergy & Clinical Immunology, 120(5 Suppl): S94-138. http://www.nhlbi.nih.gov/guidelines/asthma/
- Qureshi, F.A., Zaritsky, A., Poirier, M.(2001). Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. Journal of Pediatrics, 139, 20-26. <u>http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparative+efficacy+of+oral+dexamethasone+verus+oral+prednisone+in+acute+pediatric + asthma</u>
- Rowe, B.; Spooner, C.; Ducharme, F.; Bretzlaff, J.; Bota, G. (2009). Early emergency department treatment of acute asthma with systemic corticosteroids [Systematic Review]. Cochrane Database of Systematic Reviews, 1:1 <u>http://calgaryem.com/files/CD002178.pdf</u>
- Scarfone, R.J.; Fuchs, S.M.; Nager, A.L.; Shane, S.A. (1999). Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. *Pediatrics* 92(4):513 <u>http://www.ncbi.nlm.nih.gov/pubmed/8414819</u>
- Williams, K.W., Andrews, A.L., Heine, D.H. et al. (2012). Parental preference for short- versus long-course corticosteroid therapy in children with asthma presenting to the pediatric emergency department. Clinical Pediatrics. Oct 3 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/?term=Parental+preference+for+short-+versus+longcourse+corticosteroid+therapy+in+children+with+asthma+pr
- Bohannon K, Machen R, Ragsdale C, Padilla-Tolentino E, Cervenka P. Dexamethasone Associated with Significantly Shorter Length of Hospital Stay Compared to a Prednisolone Based Regimen in Pediatric Patients with Mild-Moderate Acute Asthma Exacerbations. Clinical Pediatrics 2019, accepted for publication
- Sule Doymaz, Youssef E. Ahmed, Densley Francois, Rohit Pinto, RamonGist, Miriam Steinberg & Clara Giambruno (2022) Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter?, Journal of Asthma, 59:3, 590-596, DOI: 10.1080/02770903.2020.1870130
- Giuliano JS Jr, Faustino EV, Li S, Pinto MG, Canarie MF, Carroll CL; Northeast Pediatric Critical Care Research Consortium (NEPCCRC). Corticosteroid therapy in critically ill pediatric asthmatic patients. Pediatr Crit Care Med. 2013 Jun;14(5):467-70. doi: 10.1097/PCC.0b013e31828a7451. PMID: 23628833.

Terbutaline

- Geelhoed, G. L. L.,; Le Souef, PN: Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma Annals of Emergency Medicine 23(6):1236-41, 1994 http://www.ncbi.nlm.nih.gov/pubmed/?term=Evaluation+of+SaO2+as+a+predictor+of+outco me+in+280+children+presenting+with+acute+asthma
- Bogie AL, Towne D, Luckett PM, et al. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. Pediatric Emergency Care, 23(6):355-61, 2007 <u>http://www.ncbi.nlm.nih.gov/pubmed/17572517</u>
- Carroll CL, Schramm CM. Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. Pediatric Pulmonology, 41(4):350-6, 2006 <u>http://www.ncbi.nlm.nih.gov/pubmed/16502398</u>
- Jones GH, Scott SJ. Continuous infusions of terbutaline in asthma a review. Journal of Asthma. 48(8):753-6, 2011
- http://www.ncbi.nlm.nih.gov/pubmed/21942352
- Travers AH, Milan SJ, Jones AP, et al. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane
 Database Systematic Reviews,(12), 2012 <u>http://www.ncbi.nlm.nih.gov/pubmed/23235685</u>
- Payne, D. N.; Balfour-Lynn, I. M.; Biggart, E. A.; Bush, A.; and Rosenthal, M. (2002). Subcutaneous terbutaline in children with chronic severe asthma. *Pediatric Pulmonology*, 33(5), 356-361 <u>http://onlinelibrary.wiley.com/doi/10.1002/ppul.10081/abstract</u>